Related Experiment Video
Updated: May 26, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Front-line therapy for chronic lymphocytic leukemia.
Sheetal Desai1, Javier Pinilla-Ibarz
1Department of Pharmacy, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL 33612, USA. Sheetal.Desai@moffitt.org
Cancer Control : Journal of the Moffitt Cancer Center
|December 7, 2011
Summary
Novel chemoimmunotherapy regimens and single agents significantly improve survival for chronic lymphocytic leukemia (CLL) patients. Treatment decisions require balancing efficacy with individual patient factors and adverse effects.
Area of Science:
- Hematology
- Oncology
- Clinical Therapeutics
Background:
- Chronic lymphocytic leukemia (CLL) treatment has evolved from alkylator-based therapy.
- Chemoimmunotherapy and monoclonal antibodies improve progression-free and overall survival in CLL.
- Advances in prognostic markers enhance patient outcomes in CLL.
Purpose of the Study:
- To review CLL diagnosis and prognostic factors.
- To discuss current front-line management strategies for CLL.
- To evaluate the role of prognostic factors in treatment goal setting.
Main Methods:
- Examination of diagnostic criteria for CLL.
- Analysis of prognostic factors influencing treatment decisions.
- Review of current clinical data on front-line CLL management.
Main Results:
- Both single-agent and combination therapies offer prolonged survival benefits.
- Patient comorbidities and performance status are critical in therapeutic selection.
- Cost, availability, and adverse effects must be considered alongside survival benefits.
Conclusions:
- Emerging single agents and combination therapies show promise in early-phase studies.
- Long-term survival and quality of life depend on ongoing clinical research.
- Patient enrollment in clinical trials is crucial for validating therapeutic advancements.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:16Primary Lymphoid Organs
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...